PEPG earnings analysis
What we found in PEPG's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
PepGen Inc. continues to struggle financially, reporting a net loss of $17.8 million for Q1 2026, a significant improvement from a loss of $30.2 million in Q1 2025. Operating expenses decreased by 39.5% to $18.9 million mainly due to reduced R&D costs. However, the company remains deeply in the red with no revenue from product sales, projecting substantial ongoing operational losses as they focus on the development of their lead candidate, PGN-EDODM1.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improvement in Net Loss
- Net loss decreased to $17.8M in Q1 2026 from $30.2M in Q1 2025.
- Decreased Operating Expenses
- Operating expenses fell by 39.5% to $18.9M, primarily due to a $12.4M drop in R&D expenses.
- Cash Reserves Indicate Longevity
- Cash, cash equivalents, and marketable securities totaled $132.3M, expected to sustain operations through 2027.
- Interest Income on Investments
- Interest income increased from $1.1M in Q1 2025 to $1.25M in Q1 2026.
- Maintained Stability in G&A Expenses
- General and administrative expenses remained flat at $5.9M for both Q1 2025 and Q1 2026.
- Ongoing Clinical Trials
- The company is advancing PGN-EDODM1 in clinical trials, despite regulatory challenges.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operating Losses
- The company has not generated any revenue from product sales and expects to incur losses for the foreseeable future.
- Regulatory Risks
- Partial clinical hold on the FREEDOM2 study could impact development timelines.
- Dependence on Third Parties
- Reliance on third parties for manufacturing and trial operations increases vulnerability to disruptions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.31
What they said about what is next.
The company continues to focus on PGN-EDODM1 development, but no explicit numeric guidance is provided.
The filing reads worse than the one before it.
What came before.
- 10-K · March 4, 2026
- PepGen Inc. continued to report significant operating losses in 2025, ultimately posting a net loss of $89.7 million, a slight decrease from $90.0 million in 2024, although revenue remained non-existent. Despite…
- 10-Q · November 12, 2025
- PepGen Inc. reported its Q3 2025 financial results with continued losses and no revenue generation, reflecting challenges in its clinical development program. The company’s net loss for the quarter was $18.0 million, a…
- 10-Q · August 7, 2025
- PepGen reported disappointing quarterly results with no revenue and a net loss of $23.1 million for Q2 2025, improving from a $28.3 million net loss year-over-year. Operating expenses decreased due to lower research and…
- 10-Q · May 8, 2025
- PepGen Inc. reported disappointing financial results for Q1 2025, with revenue of $0.0 and a net loss of $30.2 million. Operating expenses surged to $31.3 million primarily due to increased research and development…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PEPG makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever